ClinicalTrials.gg
CompletedNCT04042376Updated May 25, 2025Results posted

A Study of Ibrutinib (PCI-32765) in Chinese Participants With Relapse or Refractory Waldenstrom's Macroglobulinemia (WM)

A Phase 4 interventional study of Ibrutinib in Waldenstrom Macroglobulinemia, sponsored by Janssen Research & Development, LLC. Completed at 6 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-25.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
17
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 25 studies testing ibrutinib in Waldenstrom Macroglobulinemia — 2 open to participants now, 7 under way, 2 of them phase 3. ibrutinib · Waldenstrom Macroglobulinemia.

Enrollment
20th of 25
17 · median 48
Started
2019
with 2 others
Phase 4
Only one
of the 25
Registered
18th of 25
by date
Lead sponsor
3 of 25
Janssen Research & Development, LLC

Among the 25 studies testing ibrutinib in Waldenstrom Macroglobulinemia, this one is the 20th largest by enrollment, is one of 3 that started in 2019, is the only one in phase 4, and was the 18th registered.

Waldenstrom Macroglobulinemia

524 studies on the registry are indexed under Waldenstrom Macroglobulinemia; 61 are open to participants now.

Browse Waldenstrom Macroglobulinemia studies →

Open to participants now

2 of the 25 studies testing ibrutinib in Waldenstrom Macroglobulinemia are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About ibrutinib

ibrutinib: first FDA approval 2013 (IMBRUVICA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 47 Waldenstrom Macroglobulinemia studies recruiting now, 43 (91%) set no upper age limit and 1 (2%) stops at 75 or younger; 2 take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies testing ibrutinib in Waldenstrom Macroglobulinemia, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy of ibrutinib based on overall response rate (ORR) (partial response [PR] or better) by investigator assessment per the modified Consensus Response Criteria from the Sixth International Workshop on Waldenstrom's Macroglobulinemia (IWWM) (NCCN 2019), in Chinese participants with relapsed or refractory waldenstrom's macroglobulinemia.

03

Conditions studied

  • Waldenstrom Macroglobulinemia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and women greater than or equal to (>=) 18 years of age
  • (ECOG) less than or equal to (\<=) 2
  • Previously received at least one prior therapy for WM and have had either documented disease progression or had no response to the most recent treatment regimen
  • Centrally confirmed clinicopathological diagnosis of WM
  • defined as serum monoclonal immunoglobulin M (IgM) >0.5 gram per deciliter (g/dL)
  • Symptomatic disease, requiring treatment
  • Hematology and biochemical values within protocol-defined limits
  • Female participants of must have a negative serum pregnancy test at screening and agree to use highly effective methods of while taking study drug. Female participants of childbearing potential should avoid becoming pregnant while taking ibrutinib and for up to 1 month after the last dose of study drug. Male participants must use an effective barrier method of contraception during the study and for 3 months following the last dose of ibrutinib if sexually active with a female of childbearing potential

Exclusion criteria

Exclusion Criteria:

  • Involvement of the central nervous system by WM
  • Evidence of disease transformation
  • Prior exposure to BTK inhibitors
  • Known reaction to ibrutinib or to the in its formulation
  • Received any WM-related therapy \<=30 days prior to first administration of study treatment
  • Received a prior hematopoietic stem cell transplant
  • Plasmapheresis \<35 days prior to the initiation of study drug, except when at least one serum IgM central assessment was performed during the screening period and was >35 days from the most recent plasmapheresis procedure
  • History of other , except: (a) malignancy treated with curative intent and with no known active disease present for >=2 years before the first dose of study drug and felt to be at low risk for recurrence by treating physician; (b) adequately treated nonmelanoma skin cancer or lentigo maligna without evidence of disease; (c) adequately treated carcinoma in situ without evidence of disease
  • Vaccinated with live, attenuated vaccines within 4 weeks of first dose of study drug
  • Infection requiring systemic treatment that was completed \<=14 days before the first dose of study drug
  • Bleeding disorders or hemophilia
  • Stroke or intracranial hemorrhage within 6 months prior to enrollment
  • Infection with (HIV) or active infection with or
  • Major surgery within 4 weeks of first dose of study drug
  • Any life-threatening illness, medical condition, or organ system dysfunction that, in the investigator's opinion, could compromise the participant's safety or put the study outcomes at undue risk
  • Currently active, hepatic impairment Class B or C according to the Child Pugh classification
  • Currently active, clinically significant cardiovascular disease
  • Requires or receiving anticoagulation with warfarin or other Vitamin K antagonists
  • Unable to swallow capsules or malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel, symptomatic inflammatory bowel disease or ulcerative colitis, or partial or complete bowel obstruction
  • Requires treatment with a strong cytochrome P450 (CYP) 3A inhibitor
  • Lactating or pregnant
  • Unable to understand the purpose and risks of the study and to provide a signed and dated form (ICF) and authorization to use protected health information (in accordance with national and local participant privacy regulations)
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
17 participants (actual)

Study arms

  • Experimental
    Ibrutinib 420 milligram (mg)

    Participants will receive ibrutinib 420 mg once daily, continuously starting at Day 1 of Week 1 until disease progression or unacceptable toxicity, whichever occurs first.

    Drug: Ibrutinib

Interventions

  • Ibrutinib will be administered orally, once daily, at a dose of 420 mg (140 mg\*3 capsules taken together at one time).

    Also known as: JNJ-54179060, PCI-32765

06

What researchers measure

Primary outcomes

  1. Overall Response Rate (ORR)

    ORR was defined as the percentage of participants who achieved partial response (PR) or better (VGPR) per the modified consensus response criteria from sixth International Workshop on Waldenstrom's Macroglobulinemia (IWWM) (National Comprehensive Cancer Network \[NCCN\], 2019). PR: greater than or equal to (\>=) 50 percent (%) reduction of serum immunoglobulin M (IgM) from baseline, with reduction in lymphadenopathy/splenomegaly if present at baseline. Very Good Partial Response (VGPR): \>=90% reduction of serum IgM from baseline or normal serum IgM values, with reduction in lymphadenopathy/splenomegaly if present at baseline.

    Time frame: From start of the treatment (Day 1) up to 49.3 months

Secondary outcomes

  1. Clinical Response Rate (CRR)

    CRR was defined as the percentage of participants who achieved minor response (MR) or better according to the modified sixth IWWM (NCCN 2019) criteria as assessed by the investigator. MR: \>=25% but less than (\<) 50% reduction of serum IgM from baseline.

    Time frame: From start of the treatment (Day 1) up to 49.3 months

  2. Very Good Partial Response (VGPR) or Better Response Rate

    VGPR or better response rate was defined as the percentage of participants who achieved VGPR or better according to the modified sixth IWWM (NCCN 2019) criteria as assessed by the investigator. VGPR: \>=90% reduction of serum IgM from baseline or normal serum IgM values, with reduction in lymphadenopathy/splenomegaly if present at baseline.

    Time frame: From start of the treatment (Day 1) up to 49.3 months

  3. Duration of Response (DOR)

    DOR: duration from date of initial documentation of response (PR/better) to date of first documented progressive disease(PD), death or date of censoring if applicable, for responders (PR/better), as assessed by investigator. VGPR/PR: \>=90% reduction or normal serum IgM values (for VGPR) and \>=50% (for PR) reduction of serum IgM, with reduction in lymphadenopathy/splenomegaly if present at baseline. PD(at least 1): \>=25% IgM increase in serum IgM with \>=500 milligrams per deciliters(mg/dL) increase from nadir(lowest serum IgM value at any time from baseline), confirmation needed if IgM was sole PD criterion; new lymph nodes \>1.5 centimeters(cm), \>=50% increase in nadir in sum of product of diameters; 50% increase in longest diameter of previously identified node \>1cm in short axis; new splenomegaly; new extranodal disease; new/recurrent bone marrow involvement; new symptomatic disease(pleural effusion/Bing Neel syndrome/amyloidosis/light chain deposition/paraprotein mediated disorder).

    Time frame: From the date of first documented response up to date of first documented PD or death (Day 1 up to 49.3 months)

  4. Time to Response (TTR)

    TTR was defined as the time from the date of first dose to the date of initial documentation of a response (PR or better) for responders. PR: \>=50% reduction of serum IgM from baseline, with reduction in lymphadenopathy/splenomegaly if present at baseline. VGPR: \>=90% reduction of serum IgM from baseline or normal serum IgM values, with reduction in lymphadenopathy/splenomegaly if present at baseline.

    Time frame: From start of the treatment up to first documentation of PR or better (Day 1 up to 49.3 months)

  5. Progression Free Survival (PFS)

    PFS was defined as duration from the date of first dose to the date of disease progression or death, whichever occurs first, assessed according to the modified sixth IWWM (NCCN 2019) criteria. PD (at least 1 of the following): \>=25% IgM increase in serum IgM with \>=500 mg/dL increase from nadir (lowest serum IgM value at any time from baseline), confirmation needed if IgM was sole PD criterion; new lymph nodes \>1.5 cm, \>=50% increase in nadir in sum of product of diameters; 50% increase in longest diameter of previously identified node \>1 cm in short axis; new splenomegaly; new extranodal disease; new/recurrent bone marrow involvement; new symptomatic disease (pleural effusion, Bing Neel syndrome, amyloidosis, light chain deposition, paraprotein mediated disorder).

    Time frame: From day of first dose (Day 1) until PD or death (up to 49.3 months)

  6. Overall Survival (OS)

    Overall survival was measured from the date of first dose to the date of the participant's death from any cause.

    Time frame: From day of first dose (Day 1) until death due to any cause (up to 49.3 months)

  7. Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Grade 3 or Higher TEAEs

    An adverse event (AE) was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. TEAEs were defined as AEs occurring after the first dose of study drugs and within 30 days following the last dose of study drug or initiation of subsequent antineoplastic treatment, whichever occurred earlier. TEAEs were graded based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 4.03 as Grade 1= Mild; Grade 2= Moderate; Grade 3= Severe; Grade 4= Life-threatening and Grade 5= Death. Number of participants with TEAEs and Grade 3 or higher TEAEs (included serious and non-serious events) were reported in this outcome measure.

    Time frame: From start of the treatment (Day 1) up to 30 days after last dose or initiation of subsequent antineoplastic treatment, whichever occurred first (Day 1 up to 45.9 months)

  8. Plasma Concentration of Ibrutinib

    Plasma concentrations of ibrutinib were reported.

    Time frame: Pre-dose on Day 1 of Weeks 1, 5 and 9

07

Results

Posted Apr 16, 2025

Participant flow

Participant flow — Overall Study
MilestoneIbrutinib 420 mg
Started17
Completed13
Not completed4
Withdrew: Withdrawal by subject1
Withdrew: Death3

Outcome measures

PrimaryOverall Response Rate (ORR)

ORR was defined as the percentage of participants who achieved partial response (PR) or better (VGPR) per the modified consensus response criteria from sixth International Workshop on Waldenstrom's Macroglobulinemia (IWWM) (National Comprehensive Cancer Network \[NCCN\], 2019). PR: greater than or equal to (\>=) 50 percent (%) reduction of serum immunoglobulin M (IgM) from baseline, with reduction in lymphadenopathy/splenomegaly if present at baseline. Very Good Partial Response (VGPR): \>=90% reduction of serum IgM from baseline or normal serum IgM values, with reduction in lymphadenopathy/splenomegaly if present at baseline.

Time frame:
From start of the treatment (Day 1) up to 49.3 months
Reported as:
Number · Percentage of Participants
Overall Response Rate (ORR)
Percentage of ParticipantsIbrutinib 420 mg
Overall Response Rate (ORR)70.6 (47.8 to 87.6)
SecondaryClinical Response Rate (CRR)

CRR was defined as the percentage of participants who achieved minor response (MR) or better according to the modified sixth IWWM (NCCN 2019) criteria as assessed by the investigator. MR: \>=25% but less than (\<) 50% reduction of serum IgM from baseline.

Time frame:
From start of the treatment (Day 1) up to 49.3 months
Reported as:
Number · Percentage of Participants
Clinical Response Rate (CRR)
Percentage of ParticipantsIbrutinib 420 mg
Clinical Response Rate (CRR)100.0 (83.8 to 100.0)
SecondaryVery Good Partial Response (VGPR) or Better Response Rate

VGPR or better response rate was defined as the percentage of participants who achieved VGPR or better according to the modified sixth IWWM (NCCN 2019) criteria as assessed by the investigator. VGPR: \>=90% reduction of serum IgM from baseline or normal serum IgM values, with reduction in lymphadenopathy/splenomegaly if present at baseline.

Time frame:
From start of the treatment (Day 1) up to 49.3 months
Reported as:
Number · Percentage of Participants
Very Good Partial Response (VGPR) or Better Response Rate
Percentage of ParticipantsIbrutinib 420 mg
Very Good Partial Response (VGPR) or Better Response Rate5.9 (0.3 to 25.0)
SecondaryDuration of Response (DOR)

DOR: duration from date of initial documentation of response (PR/better) to date of first documented progressive disease(PD), death or date of censoring if applicable, for responders (PR/better), as assessed by investigator. VGPR/PR: \>=90% reduction or normal serum IgM values (for VGPR) and \>=50% (for PR) reduction of serum IgM, with reduction in lymphadenopathy/splenomegaly if present at baseline. PD(at least 1): \>=25% IgM increase in serum IgM with \>=500 milligrams per deciliters(mg/dL) increase from nadir(lowest serum IgM value at any time from baseline), confirmation needed if IgM was sole PD criterion; new lymph nodes \>1.5 centimeters(cm), \>=50% increase in nadir in sum of product of diameters; 50% increase in longest diameter of previously identified node \>1cm in short axis; new splenomegaly; new extranodal disease; new/recurrent bone marrow involvement; new symptomatic disease(pleural effusion/Bing Neel syndrome/amyloidosis/light chain deposition/paraprotein mediated disorder).

Time frame:
From the date of first documented response up to date of first documented PD or death (Day 1 up to 49.3 months)
Reported as:
Median · Months
Duration of Response (DOR)
MonthsIbrutinib 420 mg
Duration of Response (DOR)20.27 (11.07 to NA)
SecondaryTime to Response (TTR)

TTR was defined as the time from the date of first dose to the date of initial documentation of a response (PR or better) for responders. PR: \>=50% reduction of serum IgM from baseline, with reduction in lymphadenopathy/splenomegaly if present at baseline. VGPR: \>=90% reduction of serum IgM from baseline or normal serum IgM values, with reduction in lymphadenopathy/splenomegaly if present at baseline.

Time frame:
From start of the treatment up to first documentation of PR or better (Day 1 up to 49.3 months)
Reported as:
Median · Months
Time to Response (TTR)
MonthsIbrutinib 420 mg
Time to Response (TTR)3.71 (1.84 to 3.71)
SecondaryProgression Free Survival (PFS)

PFS was defined as duration from the date of first dose to the date of disease progression or death, whichever occurs first, assessed according to the modified sixth IWWM (NCCN 2019) criteria. PD (at least 1 of the following): \>=25% IgM increase in serum IgM with \>=500 mg/dL increase from nadir (lowest serum IgM value at any time from baseline), confirmation needed if IgM was sole PD criterion; new lymph nodes \>1.5 cm, \>=50% increase in nadir in sum of product of diameters; 50% increase in longest diameter of previously identified node \>1 cm in short axis; new splenomegaly; new extranodal disease; new/recurrent bone marrow involvement; new symptomatic disease (pleural effusion, Bing Neel syndrome, amyloidosis, light chain deposition, paraprotein mediated disorder).

Time frame:
From day of first dose (Day 1) until PD or death (up to 49.3 months)
Reported as:
Median · Months
Progression Free Survival (PFS)
MonthsIbrutinib 420 mg
Progression Free Survival (PFS)23.95 (14.69 to NA)
SecondaryOverall Survival (OS)

Overall survival was measured from the date of first dose to the date of the participant's death from any cause.

Time frame:
From day of first dose (Day 1) until death due to any cause (up to 49.3 months)
Reported as:
Median · Months
Overall Survival (OS)
MonthsIbrutinib 420 mg
Overall Survival (OS)NA (NA to NA)
SecondaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs) and Grade 3 or Higher TEAEs

An adverse event (AE) was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. TEAEs were defined as AEs occurring after the first dose of study drugs and within 30 days following the last dose of study drug or initiation of subsequent antineoplastic treatment, whichever occurred earlier. TEAEs were graded based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 4.03 as Grade 1= Mild; Grade 2= Moderate; Grade 3= Severe; Grade 4= Life-threatening and Grade 5= Death. Number of participants with TEAEs and Grade 3 or higher TEAEs (included serious and non-serious events) were reported in this outcome measure.

Time frame:
From start of the treatment (Day 1) up to 30 days after last dose or initiation of subsequent antineoplastic treatment, whichever occurred first (Day 1 up to 45.9 months)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Grade 3 or Higher TEAEs
ParticipantsIbrutinib 420 mg
TEAEs17
Grade 3 or Higher TEAEs15
SecondaryPlasma Concentration of Ibrutinib

Plasma concentrations of ibrutinib were reported.

Time frame:
Pre-dose on Day 1 of Weeks 1, 5 and 9
Reported as:
Mean · Nanograms per milliliter (ng/mL)
Plasma Concentration of Ibrutinib
Nanograms per milliliter (ng/mL)Ibrutinib 420 mg
Predose Day 1 Week 1NA ± NA
Predose Day 1 Week 53.46 ± 3.97
Predose Day 1 Week 96.27 ± 8.36

Adverse events

Collected over All-cause mortality: From Day 1 up to 49.3 months; Serious and other adverse events: From first dose of study drug (Day 1) up to 30 days after last dose of study drug (up to 45.9 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ibrutinib 420 mg3/17 (17.6%)9/17 (52.9%)17/17 (100%)
Most frequent serious events
Showing 10 of 12
Most frequent serious events
EventIbrutinib 420 mg
Anal AbscessInfections and infestations1/17
Bacterial ProstatitisInfections and infestations1/17
Covid-19 PneumoniaInfections and infestations1/17
OrchitisInfections and infestations1/17
PneumoniaInfections and infestations1/17
FractureInjury, poisoning and procedural complications1/17
Lumbar Vertebral FractureInjury, poisoning and procedural complications1/17
Lung Squamous Cell Carcinoma Stage 0Neoplasms benign, malignant and unspecified (incl cysts and polyps)1/17
Haemorrhage IntracranialNervous system disorders1/17
Peripheral Sensory NeuropathyNervous system disorders1/17
Most frequent other events
Showing 10 of 75
Most frequent other events
EventIbrutinib 420 mg
HyperuricaemiaMetabolism and nutrition disorders11/17
AnaemiaBlood and lymphatic system disorders6/17
Upper Respiratory Tract InfectionInfections and infestations5/17
Neutrophil Count DecreasedInvestigations5/17
White Blood Cell Count DecreasedInvestigations5/17
HypoalbuminaemiaMetabolism and nutrition disorders5/17
EczemaSkin and subcutaneous tissue disorders4/17
Abdominal Pain UpperGastrointestinal disorders3/17
Platelet Count DecreasedInvestigations3/17
Weight IncreasedInvestigations3/17

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Ibrutinib 420 mg
Mean64.1 ± 6.95
Sex: Female, Male
Sex: Female, Male(Participants)Ibrutinib 420 mg
Female7
Male10
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Ibrutinib 420 mg
Asian/Not Hispanic or Latino17
08

Study locations

6 sites
  • The First Hospital of Jilin University
    Changchun, 130021, China
  • First affiliated Hospital of Zhejiang University
    Hangzhou, 310003, China
  • Institute of Hematology and Blood Diseases Hospital
    Tianjin, 300320, China
  • Wuhan Union Hospital
    Wuhan, 430023, China
  • The Second Affiliated Hospital of Xi'an Jiaotong University
    Xi'an, 710004, China
  • Henan Cancer Hospital
    Zhengzhou, 450008, China
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Data sharing details ↗ · www.janssen.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2019 to primary completion in Mar 2024, 51 months.

Results were first posted in Apr 2025, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 31, 2019
First posted
Aug 1, 2019
StartActual
Dec 18, 2019
Primary completionActual
Mar 19, 2024
CompletionActual
Mar 19, 2024
Results first posted
Apr 16, 2025
Last update
May 25, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04042376
Responsible party
Sponsor
First posted
Aug 1, 2019
Start date
Dec 18, 2019
Primary completion
Mar 19, 2024
Completion
Mar 19, 2024
Results posted
Apr 16, 2025
Last update
May 25, 2025

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ibrutinib

Start the discussion